Oncology Clinical Briefing: Expert Insights for Managing Breast Cancer in the Time of COVID-19

As the novel coronavirus, SARS-CoV-2, spreads across the globe, and as confirmed cases of COVID-19 infection continue to climb, we are being ushered into circumstances which are unprecedented in modern times. It is thus absolutely vital that oncology clinicians, who manage a patient population at very high risk for severe manifestations of COVID-19, be informed regarding adaptive ways to keep their patients safe. To help meet that need, this online educational activity will review the ever-changing epidemiology of COVID-19 and identify primary infection risk concerns for cancer patients. It will also evaluate responsive institutional and clinical protocols that are effective in simultaneously mitigating COVID-19 transmission and optimizing cancer care, as well as offer viewers an expert-led exploration of emerging guidelines and clinical trial data. Lastly, experts on the front lines will discuss forward-thinking strategies oncology clinicians can employ to outpace the pandemic and provide uninterrupted, high-quality care for patients.

Target Audience

This online educational activity is targeted to medical oncologists, surgical oncologists, radiation oncologists, primary care physicians, and other clinicians who manage patients with breast cancer.

Learning Objectives

  • Review the evolving epidemiology of the novel coronavirus (SARS-CoV-2) outbreak, and identify key infection risk considerations for clinicians managing patients with breast cancer, including risk factors and hallmark symptomatology.
  • Evaluate adaptive institutional and clinical protocols for mitigating transmission of COVID-19 while maintaining high integrity cancer care.
  • Examine emerging guidelines for patient priority stratification based on risk vs. benefit analyses, and appraise early data from ongoing COVID-19 clinical trials.
  • Discuss forward-thinking strategies oncology clinicians can employ to “stay ahead” of the pandemic and optimize outcomes for their patients.
Course summary
Available credit: 
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Course opens: 
Course expires: 

Komal Jhaveri, MD
Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY


Rita Nanda, MD
Director, Breast Oncology Program
The University of Chicago Medicine
Chicago, Illinois


Sara Toleny, MD, MPH
Associate Director, Susan F. Smith Center for Women's Cancers
Director, Clinical Trials, Breast Oncology
Assistant Professor of Medicine
Harvard Medical School


In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.

Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as an entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.

Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

Bryan Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.

Komal Jhaveri, MD–has no relevant financial relationships to disclose in relation to the content of this activity.
Rita Nanda, MD-Rita Nanda, MD—has disclosed that she is a consultant for Aduro, Clovis, Daiichi Sankyo, Inc., Genentech, MacroGenics, Merck, and Pfizer. She receives grant/research support from AstraZeneca, Celgene, Corcept Therapeutics, Genentech/Roche, Immunomedics, Merck, OBI Pharm, Inc., Odonate Therapeutics, Pfizer, and Seattle Genetics. She receives financial support from G1 Therapeutics (DSMB).
Sara Tolaney, MD–has no relevant financial relationships to disclose in relation to the content of this activity.

Available Credit

  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 Participation
Please login or register to take this course.